View DividendRegnum マネジメントマネジメント 基準チェック /04現在、CEO に関する十分な情報がありません。主要情報 最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間no dataCEOの所有権n/a経営陣の平均在職期間データなし取締役会の平均在任期間データなし経営陣の近況お知らせ • Jun 01Regnum Corp. Announces Resignation of Anne Kirby as Sole Member of Board of DirectorsOn May 23, 2023, Anne Kirby provided formal notice of her resignation as Chief Executive Officer and as the sole member of the board of directors of Regnum Corp. (the “Company”). Ms. Kirby’s resignation was for personal reasons and not a result of a disagreement relating to the Company’s operations, policies or practices. The Company and its majority shareholder have begun the process to fill the board and officer vacancies with suitable candidates.すべての更新を表示Recent updatesお知らせ • Jun 01Regnum Corp. Announces Resignation of Anne Kirby as Sole Member of Board of DirectorsOn May 23, 2023, Anne Kirby provided formal notice of her resignation as Chief Executive Officer and as the sole member of the board of directors of Regnum Corp. (the “Company”). Ms. Kirby’s resignation was for personal reasons and not a result of a disagreement relating to the Company’s operations, policies or practices. The Company and its majority shareholder have begun the process to fill the board and officer vacancies with suitable candidates.お知らせ • Aug 17Regnum Corp. announced delayed 10-Q filingOn 08/16/2022, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Regnum Corp. announced delayed 10-Q filingOn 05/16/2022, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01Regnum Corp. announced delayed annual 10-K filingOn 03/31/2022, Regnum Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Sep 02SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. (OTCPK:RGMP) from Phoenixus AG in a reverse merger transaction.SevenScore Pharmaceuticals LLC made a proposal to acquire Regnum Corp. (OTCPK:RGMP) from Phoenixus AG and others in a reverse merger transaction for $9.8 million on April 7, 2021. SevenScore Pharmaceuticals LLC entered into an agreement to acquire Regnum Corp. from Phoenixus AG and others in a reverse merger transaction on May 13, 2021. Phoenixus AG (“PAG”) owns approximately 98.9% stake in Regnum. Upon closing, membership interests in SevenScore will be converted into the right to receive an aggregate of 25.9 million shares of common stock of Regnum. Upon effectiveness of the Merger, (i) each share of Regnum Common Stock issued and outstanding and owned by PAG as of immediately prior thereto shall be cancelled and extinguished without any conversion thereof, and (ii) 22,730,409 shares of Regnum Common Stock will be owned by PAG as a result of conversion of SevenScore membership interests; (ii) 3,147,759 shares of RGMP Common Stock being owned by several other SevenScore members; and (iii) 250,000 shares of Regnum Common Stock being owned by the Regnum shareholders, other than PAG, prior to effectiveness of the Merger. The equity holders, or members, of SevenScore will receive a majority of the shares of common stock of Regnum in the merger. The completion of the Merger is subject to satisfaction to submit a Company Related Action Notification in accordance with Financial Industry Regulatory Authority (FINRA) Rule 6490. The board of directors of Regnum and SevenScore have unanimously approved the transaction. PAG, the majority shareholder of Regnum also approved the transaction. SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. (OTCPK:RGMP) from Phoenixus AG in a reverse merger transaction on September 1, 2021. No fees or penalties were paid in connection with the termination of the agreement.お知らせ • Aug 18Regnum Corp. announced delayed 10-Q filingOn 08/17/2021, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 03Regnum Corp. announced delayed annual 10-K filingOn 04/01/2021, Regnum Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 18Regnum Corp. announced delayed 10-Q filingOn 08/17/2020, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.CEORegnum CEOがいない、あるいは彼らに関するデータがない。View Ownership企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/10/09 20:47終値2024/07/12 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Regnum Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 01Regnum Corp. Announces Resignation of Anne Kirby as Sole Member of Board of DirectorsOn May 23, 2023, Anne Kirby provided formal notice of her resignation as Chief Executive Officer and as the sole member of the board of directors of Regnum Corp. (the “Company”). Ms. Kirby’s resignation was for personal reasons and not a result of a disagreement relating to the Company’s operations, policies or practices. The Company and its majority shareholder have begun the process to fill the board and officer vacancies with suitable candidates.
お知らせ • Jun 01Regnum Corp. Announces Resignation of Anne Kirby as Sole Member of Board of DirectorsOn May 23, 2023, Anne Kirby provided formal notice of her resignation as Chief Executive Officer and as the sole member of the board of directors of Regnum Corp. (the “Company”). Ms. Kirby’s resignation was for personal reasons and not a result of a disagreement relating to the Company’s operations, policies or practices. The Company and its majority shareholder have begun the process to fill the board and officer vacancies with suitable candidates.
お知らせ • Aug 17Regnum Corp. announced delayed 10-Q filingOn 08/16/2022, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Regnum Corp. announced delayed 10-Q filingOn 05/16/2022, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01Regnum Corp. announced delayed annual 10-K filingOn 03/31/2022, Regnum Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Sep 02SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. (OTCPK:RGMP) from Phoenixus AG in a reverse merger transaction.SevenScore Pharmaceuticals LLC made a proposal to acquire Regnum Corp. (OTCPK:RGMP) from Phoenixus AG and others in a reverse merger transaction for $9.8 million on April 7, 2021. SevenScore Pharmaceuticals LLC entered into an agreement to acquire Regnum Corp. from Phoenixus AG and others in a reverse merger transaction on May 13, 2021. Phoenixus AG (“PAG”) owns approximately 98.9% stake in Regnum. Upon closing, membership interests in SevenScore will be converted into the right to receive an aggregate of 25.9 million shares of common stock of Regnum. Upon effectiveness of the Merger, (i) each share of Regnum Common Stock issued and outstanding and owned by PAG as of immediately prior thereto shall be cancelled and extinguished without any conversion thereof, and (ii) 22,730,409 shares of Regnum Common Stock will be owned by PAG as a result of conversion of SevenScore membership interests; (ii) 3,147,759 shares of RGMP Common Stock being owned by several other SevenScore members; and (iii) 250,000 shares of Regnum Common Stock being owned by the Regnum shareholders, other than PAG, prior to effectiveness of the Merger. The equity holders, or members, of SevenScore will receive a majority of the shares of common stock of Regnum in the merger. The completion of the Merger is subject to satisfaction to submit a Company Related Action Notification in accordance with Financial Industry Regulatory Authority (FINRA) Rule 6490. The board of directors of Regnum and SevenScore have unanimously approved the transaction. PAG, the majority shareholder of Regnum also approved the transaction. SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. (OTCPK:RGMP) from Phoenixus AG in a reverse merger transaction on September 1, 2021. No fees or penalties were paid in connection with the termination of the agreement.
お知らせ • Aug 18Regnum Corp. announced delayed 10-Q filingOn 08/17/2021, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 03Regnum Corp. announced delayed annual 10-K filingOn 04/01/2021, Regnum Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 18Regnum Corp. announced delayed 10-Q filingOn 08/17/2020, Regnum Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.